MolecularHealth Launches Molecular Analysis of Side Effects™ (MASE), a Next-Generation Drug Safety Assessment and Prediction Technology

NEW YORK, Jan. 18, 2012 /PRNewswire/ -- MolecularHealth, a clinico-molecular informatics company, today announced the launch of Molecular Analysis of Side Effects (MASE), its flagship drug safety assessment and prediction tool that enables mechanism-based safety analysis for all drugs currently on the market, along with the identification of potential adverse events for drugs in development.

MASE is the first technology of its kind to combine adverse event information from spontaneous reporting systems with clinico-molecular knowledge about drug activity within a patient to enable the exploration and analysis of a drug's safety profile from both molecular and statistical perspectives. The system's robust analytical and visualization tools incorporate information from peer-reviewed literature to enable efficient detection and validation of safety signals, providing a range of users with timely and actionable information for critical drug decision-making.

"In 2011, the FDA outlined goals for its new mechanism-based drug safety assessment and prediction program, including mapping potential drug toxicities to the molecular level," said Jeffrey D. Marrazzo, chief business officer of MolecularHealth. "We believe that MASE's capabilities are consistent with this mandate, providing regulators, drug developers and payers with a highly innovative technology to enhance drug safety."

David Jackson, Ph.D., chief scientific officer at MolecularHealth said, "Until now, drug safety signal detection and analysis have relied on the collection and collation of retrospective observational data, oftentimes post-approval. MASE is a powerful tool that enables the proactive detection, analysis and prediction of safety signals before they become prevalent in patients."

MASE's capabilities include:

• Safety signal detection and analysis
• Exploration and prediction of potentially causative molecular mechanisms
• Analysis of adverse event data for drugs, drug classes, targets or pathways
• Comparative effectiveness and comparative safety analyses
• Definition and analysis of virtual patient cohorts
• Molecular analysis of individual patients
• Extendible to include results from clinical trial and adverse drug event management programs

About MolecularHealth

MolecularHealth, a clinico-molecular informatics company, is advancing precision medicine by translating patient-specific molecular and genomic data, clinical history and published scientific evidence into safer, more effective drug choices. The company maintains offices in Basel, Switzerland; Heidelberg, Germany; Houston and New York and is backed by the co-founder, former chairman and chief executive officer of SAP, Dietmar Hopp, through dievini Hopp BioTech. MolecularHealth team members were instrumental in the development of data analysis software used during the Human Genome Project, and today the company continues to build upon this heritage as a clinical IT development partner for health and hospital systems worldwide. The company is led by a team of seasoned entrepreneurs, scientists and technologists, including founding members of Generation Health, LION Bioscience, Model N Life Sciences and Xapien. 

SOURCE MolecularHealth